Ovid Therapeutics Q1 net loss widens as R&D spending rises

Ovid Therapeutics

12/05/2026 12:11

Overview

US biopharma firm reported a wider net loss year-over-year

Higher R&D spending drove increased operating expenses as clinical programs expanded

Outlook

Ovid expects current cash resources to fund operations into 2029

Result Drivers

R&D EXPANSION - Higher research and development expenses driven by increased preclinical and clinical study activities for OV329 and OV4071

PIPELINE PROGRESS - Initiation of Phase 1 study for OV4071 and expansion of OV329 into new pediatric indications contributed to higher costs

Company press release: ID:nGNX2KNhJb

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.12
Q1 Net Income
-$16.99 mln
Q1 Operating Expenses
$17.85 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Ovid Therapeutics Inc is $5.00, about 79.2% above its May 11 closing price of $2.79

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)